ACADEMIA
Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
The Japan Society of Hepatology plans to shortly announce an updated version of its hepatitis C treatment guidelines, which will reflect the use of Bristol-Myers Squibb’s triple direct-acting antiviral combo Ximency (daclatasvir + asunaprevir + beclabuvir). Teikyo University Prof. Atsushi…
To read the full story
Related Article
ACADEMIA
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





